Alaunos Therapeutics (WEK0) Stock Price & Analysis

WEK0 Stock Chart & Stats

€1.00€0.00(0.00%)

At close: Oct 30 5:30 PM GMT+1

No data to display

Day’s Range: EUR 1.00 - EUR 1.01
52-Week Range: EUR 1.00 - EUR 1.01
Previous Close: EUR 1.00
Volume: 0
Average Volume (3M): 0
Market Cap: EUR 6.29M
Enterprise Value: EUR 3.47M
Total Cash (Recent Filing): EUR 124.00K
Total Debt (Recent Filing): EUR 0
Price to Earnings (P/E): ―
Beta: N/A
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Innovative Therapy Platform

Alaunos' proprietary TCR therapy platform harnesses the immune system to target cancer cells, offering a durable competitive advantage in oncology.

No Debt

Alaunos' lack of debt reduces financial risk, providing flexibility to pursue strategic initiatives without the burden of interest obligations.

Board Alignment With Equity

Board's decision to receive equity compensation aligns their interests with shareholders, potentially driving long-term strategic focus and performance.

Bears Say

Negative Cash Flow

Ongoing negative cash flow indicates operational cash outflows exceed inflows, necessitating external funding and impacting financial sustainability.

Lack Of Profitability

Persistent unprofitability and widening losses challenge Alaunos' ability to sustain operations and invest in growth without external capital.

Declining Equity Base

A declining equity base signals potential financial instability, limiting Alaunos' capacity to absorb losses and invest in future growth.

Alaunos Therapeutics News

Alaunos Therapeutics Regains Nasdaq Compliance After Financing

Alaunos Therapeutics ( ($TCRT) ) has shared an update. In April 2026, Alaunos Therapeutics, Inc., a Nasdaq-listed biopharmaceutical company, was notified that it no longer met the exchange’s $2.5 million

1w ago8K TCRT

Alaunos Boosts Equity With Merger and Financing Deal

Alaunos Therapeutics ( ($TCRT) ) has provided an announcement. Alaunos Therapeutics, Inc. operates in the biotechnology and pharmaceutical sector, focusing on developing cancer therapies and related immuno-oncology treatments. The company

1w ago8K TCRT

Alaunos Therapeutics announces completion of Velaris acquisition

Alaunos Therapeutics (TCRT) announced the completion of the acquisition of Velaris Therapeutics, a privately-held biotechnology company advancing a pipeline of potentially transformative therapies for pulmonary arterial hypertension and related cardiopulmonary

2w agoTCRT WEK0

Alaunos Acquires Velaris and Secures Major Financing

Alaunos Therapeutics ( ($TCRT) ) just unveiled an announcement. On October 13, 2026, Alaunos completed a stock-for-stock acquisition of Velaris Therapeutics, exchanging Velaris’ equity for Alaunos common stock and newly

2w ago8K TCRT

Alaunos Therapeutics Faces Nasdaq Delisting, Seeks Hearing

Alaunos Therapeutics ( ($TCRT) ) has issued an announcement. On April 9, 2026, Alaunos Therapeutics received notice from Nasdaq that it was not in compliance with Listing Rule 5550(b)(1), which

3w ago8K TCRT

Alaunos Therapeutics Announces New Registered Direct Offering

Alaunos Therapeutics ( ($TCRT) ) has shared an announcement. On September 18, 2026, Alaunos Therapeutics, Inc. entered into definitive agreements with institutional and accredited investors for a registered direct offering

1M ago8K TCRT

Alaunos Therapeutics prices 380,469 shares at $1.46 in registered direct offer

Alaunos Therapeutics (TCRT) announced that it has entered into definitive agreements with institutional investors in a registered direct offering for the sale of 380,469 shares of its common stock and

1M agoTCRT WEK0

Alaunos Therapeutics Updates Bylaws to Ease Shareholder Quorum

Alaunos Therapeutics ( ($TCRT) ) has issued an announcement. On September 16, 2026, Alaunos Therapeutics, Inc.’s Board of Directors approved and immediately implemented Second Amended and Restated By-Laws, replacing by-laws

1M ago8K TCRT

Alaunos Reports New Preclinical Liver Data for ALN1003

Alaunos Therapeutics ( ($TCRT) ) has provided an announcement. On June 29, 2026, Alaunos reported new preclinical statistical data from a 48-day diet-induced obesity mouse Study 1 of ALN1003, showing

4M ago8K TCRT

Alaunos Therapeutics reports metabolic improvements with ALN1003 in studies

Alaunos Therapeutics (TCRT) reported an integrated preclinical readout for ALN1003, the company’s investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. The readout consolidates findings from two

5M agoTCRT WEK0

Alaunos Reports Positive Preclinical Metabolic Data for ALN1003

Alaunos Therapeutics ( ($TCRT) ) has shared an announcement. On May 26, 2026, Alaunos Therapeutics reported an integrated preclinical readout for ALN1003, consolidating two non-GLP diet-induced obesity mouse studies and

5M ago8K TCRT

Alaunos Highlights New Preclinical Data for Obesity Therapy

Alaunos Therapeutics ( ($TCRT) ) has provided an update. On May 18, 2026, Alaunos Therapeutics reported updated non-GLP preclinical data from diet-induced obesity mouse models evaluating ALN1003, its investigational oral

5M ago8K TCRT

Alaunos Therapeutics reports updated preclinical data from ALN1003 mouse studies

Alaunos Therapeutics (TCRT) announced updated preclinical data from non-GLP diet-induced obesity mouse studies evaluating ALN1003, the company’s investigational oral metabolic therapeutic candidate. Across selected biomarker and liver histology assessments, ALN1003

5M agoTCRT WEK0

Valion Bio names Melinda Lackey as General Counsel

Valion Bio (VBIO) announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. Lackey brings nearly two decades of combined scientific and legal experience

6M agoTCRT VBIO

WEK0 FAQ

What was Alaunos Therapeutics’s price range in the past 12 months?

Alaunos Therapeutics lowest stock price was €1.00 and its highest was €1.01 in the past 12 months.

What is Alaunos Therapeutics’s market cap?

Alaunos Therapeutics’s market cap is €6.29M.

When is Alaunos Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Alaunos Therapeutics’s earnings last quarter?

Alaunos Therapeutics released its earnings results on Nov 07, 2024. The company reported -€0.628 earnings per share for the quarter.

Is Alaunos Therapeutics overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Alaunos Therapeutics pay dividends?

Alaunos Therapeutics does not currently pay dividends.

What is Alaunos Therapeutics’s EPS estimate?

Alaunos Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alaunos Therapeutics have?

Alaunos Therapeutics has 3,614,924 shares outstanding.

What happened to Alaunos Therapeutics’s price movement after its last earnings report?

Alaunos Therapeutics reported an EPS of -€0.628 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Alaunos Therapeutics?

Hedge funds hold Alaunos Therapeutics shares: the largest hedge-fund position in Alaunos Therapeutics is 118,735,132 shares, and hedge funds decreased their holdings by 26.4K shares last quarter.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alaunos Therapeutics

Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.

Alaunos Therapeutics (WEK0) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	10	1	4
Technical Analysis	2	1	0
Moving Averages	8	0	4

Technical Analysis >

Similar Stocks

Stocks similar to DE:WEK0
Company	Price & Change	Follow
AIMAIM ImmunoTech
GRIGRI Bio
CLDICalidi Biotherapeutics

Compare DE:WEK0 Stocks >

Ownership Overview

8.92% Insiders
1.56% Mutual Funds
<0.01% Other Institutional Investors
89.13% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft